Inquiry Basket
BOC Sciences builds more complete one-stop solution platform for antibody-drug conjugate (ADC) drug development. Since its establishment, BOC Sciences has been cooperating with companies and academic groups around the world, including most of the top biopharmaceutical companies, to support their development and manufacturing of antibody-drug conjugates. Its comprehensive products and R&D solutions promote drug discovery and biomedical research of pharmaceutical companies and researchers.
With its state-of-the-art equipment and unique R&D expertise, BOC Sciences can provide personalized antibody modification and coupling technologies with high specificity and high affinity within a short turnaround time. The strategies for antibody modification and conjugation include cysteine conjugate, lysine-based binding, carbohydrate conjugate, unnatural amino acids conjugation and other conjugation approaches.
The cytotoxic payload or warhead is an important part of ADC. It is activated after being released from ADC in the cytoplasm of tumor cells and can destroy tumor cells even at low doses.
Recently, the FDA has cleared an Investigational New Drug (IND) application allowing RemeGen, China-based biopharmaceutical company, to initiate a Phase II clinical trial of Disitamab Vedotin, to test the drug as...
Antibodies are the precise guidance components of ADCs. In theory, molecules that bring effector molecules to the surface of tumor cells can play the role of antibody guidance.
The number of cytotoxic drugs connected to each antibody is the drug-to-antibody ratio (DAR). When the DAR increases, the drug metabolism rate of ADC drugs increases, the half-life decreases, and the systemic toxicity increases. Ideally, when the DAR is 4, the drug has the highest efficacy.
